title: Oral low-dose etoposide therapy for refractory multiple myeloma with extramedullary involvement.
abstract: A 65-year-old man was hospitalized with IgG kappa-type multiple myeloma (MM) and enormous subcutaneous plasmacytomas. Two different combination chemotherapy regimens (MMCP and AVPP) and alpha-interferon therapy were ineffectual. Oral administration of etoposide at 50 mg/day was subsequently started, the tumors completely disappeared after 5 months. The blood level of monoclonal protein became undetectable after 8 months of continuous treatment. The side effect noted was loss of hair. The course in this patient suggests that long-term daily low-dose administration of etoposide should be attempted in patients with refractory MM and extramedullary plasmacytoma.
authors.affiliation: Second Department of Internal Medicine, Aichi Medical College.
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
authors.forename: H
authors.initials: H
authors.lastname: Takeda
authors.forename: H
authors.initials: H
authors.lastname: Mihara
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Kamijima
authors.forename: M
authors.initials: M
authors.lastname: Kuwahara
authors.forename: T
authors.initials: T
authors.lastname: Oguri
authors.forename: T
authors.initials: T
authors.lastname: Nagasaka
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D011344:Procarbazine; D005047:Etoposide; D004317:Doxorubicin; D011239:Prednisolone